Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 4Leukemia, Biphenotypic, Acute 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neuroblastoma 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 50Vincristine 49Doxorubicin 44Prednisone 42Rituximab 32Radiotherapy 27Etoposide 27Methotrexate 24Filgrastim 24Cytarabine 23Dexamethasone 15Granulocyte Colony-Stimulating Factor 13Bleomycin 13Vinblastine 12Peripheral Blood Stem Cell Transplantation 12Leucovorin 11Gene Expression Profiling 10Bortezomib 10Immunohistochemistry 9Procarbazine 8Polymerase Chain Reaction 8Gemcitabine 8Melphalan 7Amplified Fragment Length Polymorphism Analysis 7VAP-cyclo protocol 6Mercaptopurine 6Ifosfamide 6Dacarbazine 6Carmustine 6Microarray Analysis 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma × prednylidene × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡